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Mechanisms of escape from the 
PGT128 family of anti-HIV broadly neutralizing 
antibodies
Stefanie A. Krumm1, Hajer Mohammed1, Khoa M. Le2,3,4, Max Crispin5, Terri Wrin6, Pascal Poignard2,3, 
Dennis R. Burton2,3,4,7 and Katie J. Doores1*
Abstract 
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV envelope 
glycoprotein gp120 have several features that make them desirable targets for vaccine design. The PGT125-131 bnAb 
family is of particular interest due to its superior breadth and potency. The overlapping epitopes recognized by this 
family are intricate and neutralization requires interaction with at least two N-linked glycans (N332/N334, N295 or 
N301) in addition to backbone-mediated contact with the 323IGDIR327 motif of the V3 loop. We have recently shown 
that this bnAb family consists of two distinct antibody classes that can bind alternate arrangements of glycans in the 
mannose-patch in the absence of N332 thereby limiting viral escape. This led us to further investigate viral resistance 
and escape mechanisms to the PGT125-131 bnAb family.
Results: Using an escape virus isolated from the PGT125-131 donor as a guide, we show that mutating both the 
V3 core protein epitope and repositioning critical N-linked glycosylation sites are required to restore neutralization 
sensitivity. Interestingly, neutralization sensitivity could be restored via different routes for the two distinct bnAb 
classes within the PGT125-131 family, which may have been important in generating the divergence in recognition. 
We demonstrate that the observed V3 mutations confer neutralization resistance in other virus strains through both 
gain-of-function and escape studies. Furthermore, we show that the V3 loop is important in facilitating promiscuous 
binding to glycans within the mannose-patch.
Conclusions: These data highlight the importance of the V3 loop in the design of immunogens aimed at inducing 
broad and potent bnAbs that can bind promiscuously to the mannose-patch.
Keywords: HIV-1, Neutralizing antibody, Viral escape, Envelope glycoprotein, N-linked glycosylation
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Design of an immunogen that elicits broadly neutral-
izing antibodies (bnAbs) against HIV will likely be a 
key step in the development of an efficacious HIV vac-
cine [1]. Approximately 10–30  % of HIV infected indi-
viduals develop a bnAb response [2, 3] and it has been 
shown that these bnAbs, when passively administered 
to macaques, confer protection against SHIV challenge 
[4–8]. A number of bnAb sites of vulnerability have been 
identified on HIV Envelope (Env) including the CD4 
binding site, N-glycan-associated epitopes on the V1/
V2 loops (centred around N160) and the V3 loop (cen-
tred around N332) and regions on gp41 including the 
membrane proximal external region (MPER) and gp41 
glycans [9–17]. BnAbs that target the N332 glycan within 
the mannose-patch are of particular interest due to their 
superior breadth and potency and their relatively high 
frequency in HIV-infected individuals compared to other 
bnAb specificities [18–20]. BnAbs targeting this region 
have been isolated from a number of individuals and 
the prototype bnAbs include 2G12, PGT121, PGT124, 
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10-1074, PGT128, PGT130 and PGT135 [9–12, 21–24]. 
BnAb PGT121 has been shown to protect at very low 
serum concentrations in SHIV challenge studies [7] and 
to strongly suppress SHIV replication in chronically 
infected macaques [25].
The PGT125-131 family of bnAbs was isolated from 
IAVI protocol G donor 36 and have been studied exten-
sively [10, 11, 26, 27]. A crystal structure of PGT128 Fab in 
complex with the gp120 outer domain showed binding to 
N-linked glycans at positions N332 and N301 in addition 
to backbone mediated recognition of 323IGDIR327 of the 
V3 loop [10]. We have shown that this family of mannose-
patch binding bnAbs can bind promiscuously and use 
different arrangements of N-linked glycans for neutrali-
zation in the absence of the N332 glycan site [27]. More 
recently we used next generation sequencing and Immu-
niTree (a phylogenetic method [28]) to explore the evolu-
tion and diversity of the bnAb response in donor 36 and 
showed that two classes of mannose-patch binding bnAbs 
exist within this donor [26]. The first and most potent class 
(prototype PGT128) has a critical 6-amino acid insertion 
in the CDRH2 and is better able to neutralize viruses with 
an N332 glycan. The second class (prototype PGT130), 
although less potent, is more able to tolerate different gly-
can patterns in the mannose-patch and is more able to 
neutralize viruses with an N334 glycan [26]. This ability to 
bind alternate arrangements of glycans in the mannose-
patch might limit the ability of the virus to escape through 
shifting or elimination of glycan sites and led us to explore 
potential viral escape mechanisms from a promiscuous 
binding glycan bnAb as found in donor 36.
Recent studies have used bnAbs against the mannose-
patch to reduce viral loads in SHIVSF162P3 and YU2 
chronically infected macaques and humanized mice 
respectively. In YU2 infected mice, escape from bnAbs 
10-1074 and PGT128 occurred through elimination of 
the N332 glycan site [29]. However, rapid control of virus 
was observed in these mice when 10-1074 and PGT128 
were administered in combination with 3BC176, PG16 
and 45-46G54W. For SHIVSF162P3 infected macaques, 
PGT121 alone rapidly reduced viral replication but no 
viral escape was observed [25]. Similarly, Moore et  al. 
have shown, in an HIV-infected individual, that escape 
from an N332-dependant bnAb response can occur 
through shifting of the N332 glycan site to the N334 posi-
tion [30]. Therefore the common assumption has been 
that escape from mannose-patch binding bnAbs will 
likely occur through shifting or deletion of the N-linked 
glycan sites within the glycan shield. However, Sadjad-
pour et  al. recently showed that in  vivo escape from an 
N332-dependant bnAb response in an AD8 infected 
macaque occurred through a combination of mutations 
in the V3 loop [31], although these mutations did not 
confer resistance to donor 36 bnAbs PGT128 or PGT130. 
Further, Garces et al. showed that PGT124 neutralization 
resistance could occur through multiple alanine muta-
tions in the 323IGDIR327 motif in JR-CSF (D325A and 
R327A) but this also had no impact on PGT128 neutrali-
zation [11, 24].
Here we demonstrate the importance of the V3 loop 
for neutralization and promiscuous binding to the man-
nose-patch by the donor 36 bnAbs, PGTs125-131. Using 
an escape virus isolated from donor 36, we show that to 
restore neutralization sensitivity to the PGT128 bnAb 
family, mutation to both the V3 glycan positioning and 
V3 loop protein residues is required and that these muta-
tions can differ for the two bnAb branches. We dem-
onstrate that some of these V3 mutations alone or in 
combination confer neutralization resistance in other 
virus strains through both gain-of-function and escape 
studies. Furthermore, we show that mutation of the V3 
can modulate the ability of donor 36 bnAbs to bind pro-
miscuously and use alternative arrangements of N-linked 
glycans within the mannose-patch. These data highlight 
the importance of the V3 loop protein epitope for immu-
nogen design strategies aimed at inducing this diverse 
family of bnAbs through vaccination.
Results
CDRH3 interaction with V3 is critical for neutralization 
sensitivity
Previous studies had not identified the V3 loop as a 
potential escape mechanism for PGTs125-131 [11, 24, 
31]. It had been suggested that because the V3 contacts 
with PGT128 CDRH3 are mainly mediated through 
backbone hydrogen bonding and van der Waals inter-
actions, as observed in the PGT128-eODmV3 crystal 
structure, that this interaction is tolerant of side-chain 
variation [10]. However the V3-PGT128 Fab interaction 
comprises 305 Å2 of the 1081 Å2 buried surface area sug-
gesting this is an important component of the antibody 
epitope [10]. To measure the importance of this protein–
protein interaction for neutralization and gp120 binding 
we used proline-scanning mutagenesis of both the V3 
loop and CDRH3 loop of PGT128 to distort the β-strand 
interaction (Fig. 1). Previous alanine-scanning mutagene-
sis of this region had shown no effect on PGT128 neutral-
ization [11, 24]. First, the 323IGDIR327 residues of clade B 
virus JR-FL were mutated to proline, however the G324P 
and R327P mutations gave non-infectious virus. The 
other 3 mutations, I323P, D325P and I326P, all reduced 
the neutralization potency of both PGT128 and PGT130, 
albeit to varying degrees, but had little impact on 
PGV04 neutralization (a CD4 binding site bnAb control) 
(Fig. 1a). Next, mutations in the CDRH3 of PGT128 were 
made and impact on neutralization determined. Residues 
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within 100LRYTD100d were initially either reverted to that 
of the predicted germ line antibody [26] or, when the res-
idue was unchanged from germ line, mutated to proline. 
The Y100bP mutation had the largest effect abolishing 
neutralization of both JR-FL and JR-CSF viruses (Fig. 1b). 
The same effect was observed for Y100bA and Y100bR 
mutations. However, when an aromatic residue was sub-
stituted at this position (mutants Y100bW and Y100bF) 
a more modest impact on neutralization by PGT128 was 
observed highlighting the importance of a hydrophobic 
interaction with V3 at this position for neutralization. 
Mutation of PGT130 at position Y100b was also shown 
to be critical for neutralization (Fig. 1c). Combined, these 
data demonstrate the importance of the V3-CDRH3 loop 
interaction for neutralization by this family of bnAbs.
PGT128 and PGT130 do not neutralize virus isolated 
from donor 36 at the same time point
Next, to explore possible escape pathways for this family 
of bnAbs, HIV Env sequences from the time point from 
which PBMCs were isolated to generate PGTs125-131 
were obtained from donor 36 patient sera. Longitudinal 
samples were not available for this donor and therefore 
only a single time point could be studied. Unfortunately, 
only one Env sequence was identified. This was cloned 
into an Env expression vector for pseudovirus production 
and used to probe possible escape pathways by this fam-
ily of bnAbs.
The virus sequence was subtype CRF02_AG and at the 
time point PGTs125-131 were isolated had several distin-
guishing features (Fig.  2a). Firstly, there was a glycan at 
position 334 rather than the more common 332 position 
(69.9 % conserved for all HIV Env sequences (Table 1A) 
and 81.0 % conserved for subtype CRF02_AG (Table 1B), 
secondly there was an unusual proline residue at position 
326 (0.8 % conserved in all HIV Env sequences and 0 % 
conserved for subtype CRF02_AG), and thirdly there was 
no glycan at position 295 (50.2 % conserved for HIV Env 
sequences and 69 % conserved for subtype CRF02_AG). 
As expected, none of the bnAbs isolated from this donor 
were able to neutralize this virus (referred to through-
out as wild-type, WT) (Fig.  2b, c and Additional file  1: 
Figure S1). This is consistent with a number of studies 
showing that, in general, circulating HIV is resistant to 
the contemporaneous nAbs [32–34]. A control antibody, 
PGV04 [35], could neutralize the WT virus with an IC50 
of 0.50 μg/mL (Fig. 2d). 
Mutations in glycan positioning and V3 loop protein 
residues confer neutralization sensitivity for PGT128 
and PGT130
We next used site-directed mutagenesis to introduce 
mutations into Env in an attempt to confer neutraliza-
tion sensitivity to the donor 36 bnAbs. We focused ini-
tially on the V3 loop region and N-linked glycan sites 
within (N295, N301 and N332 or N334) as these had 
previously been shown to be important for neutralization 
by the donor 36 bnAbs [10, 11, 27]. These residues were 
mutated toward consensus of subtype CRF02_AG viruses 
(Table 1) and the most broad and potent bnAbs from the 
two branches, PGT128 and PGT130, along with PGT121, 
a mannose-patch binding bnAb from another Protocol 
G donor [11, 28], and the CD4 binding site bnAb PGV04 
[35] were tested. Mutations were introduced both alone 
and in combination and are summarized in Fig. 2a. Sub-
stitutions that shifted the glycan site from position 334 to 
332 alone were insufficient to confer neutralization sensi-
tivity to PGT128, PGT130 or PGT121 (Fig. 2b, c, e). Sim-
ilarly, mutation of P326 to the more commonly observed 
isoleucine (referred to as 1AA virus) alone or in combi-
nation with the N334–N332 shift was insufficient to gen-
erate neutralization sensitivity to PGT128 and PGT130 
(Fig.  2b, c). However, PGT121 neutralized virus 1AA 
N332 potently (Fig. 2e) highlighting the differences in V3 
a
b
c
Fig. 1 CDRH3 interaction with V3 is critical for neutralization by 
PGT128 and PGT130. a Residues in the 323IGDIR327 motif of JR-FL were 
mutated to proline using site-directed mutagenesis and impact on 
neutralization by PGT128, PGT130 and PGV04 determined. Mutations 
G324P and R327P produced non-infectious virus. V3 contact residues 
in the CDRH3 of b PGT128 and c PGT130 were reverted to germ line 
or mutated to proline using site-directed mutagenesis and impact 
on neutralization of JR-FL and JR-CSF determined. Data is reported as 
fold change in IC50 compared to WT (Fold change = IC50 mutant/IC50 
WT) and colour coded according to the figure key
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dependence between mannose-patch binding bnAb fam-
ilies. The neutralization potency of PGV04 was mostly 
unaffected by the mutations made (Fig. 2d).
Alignment of sequences from the Los Alamos database 
allowed additional residues to be identified within the V3 
loop that were less conserved compared to known subtype 
CRF02_AG viruses. A variant with a further two muta-
tions V307I and F330H, which are 16.8 % (V) and 1.8 % 
(F) conserved across all HIV sequences respectively and 
63 % (V) and 0 % (F) conserved among CFR02_AG viruses 
respectively (Table  1) (referred to as 3AA N332 virus), 
was neutralized by PGT128. However, the neutralization 
curve plateaued at around 75  % (Fig.  2b) and this virus 
remained resistant to PGT130 neutralization (Fig.  2c). 
The low plateau of neutralization suggested that there was 
a population of viruses that were still resistant to PGT128 
a
b c
d e
Fig. 2 Neutralization of Donor 36 escape virus by HIV bnAbs and representative sequences. a Sequence of the V3 region (residues 295–337) from 
donor 36 virus. Asparagine residues that form part of an N-linked glycosylation sequence are shown in grey. Residues that have been mutated from 
wild-type (WT) are shown in red. Neutralization of donor 36 WT and mutated viruses by b PGT128, c PGT130, d PGV04 and e PGT121
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neutralization [26, 36, 37]. We therefore looked to intro-
duce additional protein and glycan site mutations that 
might increase the neutralization plateau to 100 %. Addi-
tion of a further four mutations, H308R, E321D, V322I 
and N325D (referred to as 7AA N332 virus), resulted 
in a slightly increased neutralization plateau of 85  % for 
PGT128, and PGT130 now neutralized to approximately 
40 % at 10 μg/mL (Fig. 2b, c). The continued importance 
of the original four mutations for neutralization sensitivity 
in the 7AA N332 virus was confirmed by reverting I307, 
I326, H330 and N332 of 7AA N332 individually back to 
WT (Additional file 1: Figure S2).
As mentioned above, the WT virus did not have a gly-
can at position N295. When this glycan was introduced 
(using an I297T mutation) into the 1AA, 3AA and 7AA 
N332 variants both PGT128 and PGT130 were able to 
neutralize all viruses with a plateau of >90 % (Fig. 2b, c). 
However, the presence of the N295 glycan in the absence 
of N332 (7AA N295 N334A) was insufficient for neu-
tralization (Fig.  2b, c). Similar neutralization patterns 
were observed for the remaining bnAb family members; 
PGT125, PGT126, PGT127 and PGT131 (Additional 
file  1: Figure S1). These results show that mutation in 
both the glycan shield and the V3 loop core epitope 
are required to restore neutralization sensitivity to the 
escape virus studied.
PGT128 and PGT130 bnAb branches show different 
dependencies on V3 glycan site positioning in donor 36 
virus
We have recently used next generation sequencing 
and ImmuniTree [28] to explore the evolution of the 
bnAb response in donor 36 and to predict less mutated 
bnAbs [26]. We showed that PGT128 and 95H 71L (a 
less mutated form of PGT128) preferentially neutral-
ized N332 viruses whereas PGT130 and 74H 3L (a less 
mutated form of PGT130) preferentially neutralized 
N334 virus [26, 27]. To determine whether differing 
sensitivities of PGT128, 95H 71L, PGT130 and 74H 3L 
towards the N332 and N334 versions of the infecting 
viruses may have contributed to divergence in epitope 
recognition in this donor we generated N332 and N334 
versions of the 3AA and 7AA viruses both with and with-
out the N295 and/or the N301 glycans present (Fig. 3).
Firstly, we investigated the impact of the presence of 
the N295 glycan in the different N334 virus variants. 
PGT128 could only neutralize the N334 variant when 
the N295 glycan and all V3 mutations were also pre-
sent (i.e. 7AA N334 N295 variant, Fig. 3a). In contrast, 
PGT130 was able to neutralize both the 3AA and 7AA 
N334 variants, although again only when the N295 
glycan was also present (Fig. 3b). Of the less mutated 
bnAbs, only 95H 71L showed any activity, neutraliz-
ing only the N332 mutant viruses, albeit with a greatly 
reduced neutralization plateau (60 % compared to 80 % 
for PGT128), and the N295/N332 mutant viruses with 
plateaus of almost 100 % (Fig. 3c). 74H 3L was not able 
to neutralize any of the viruses tested (Fig. 3d).
Secondly, we looked at the impact of the glycan at N301 
in N332 and N334 viruses. Interestingly, when the N301 
glycan was removed from the 3AA N332, 3AA N295 N332, 
7AA N295 N334 and 7AA N295 N332 variant viruses, 
PGT128 was only dependent on N301 for neutralization of 
the 7AA N295 N334 virus (Fig. 3e), whereas PGT130 was 
found to be dependent on N301 for all viruses (Fig. 3f) [10, 
11]. These data further highlight different dependencies 
on N-linked glycosylation sites by the two-bnAb classes. 
Overall, in agreement with our previous observations [26, 
Table 1 Conservation of  V3 loop residues in  HIV Env 
sequences from the Los Alamos database for A) all clades 
and B) clade CRF02_AG
Values are based on 4907 and 121 sequences from the Los Alamos database for 
all clades and clade CRF02_AG respectively. Values are reported as  % occurrence 
and only the four most frequent residues are shown. N* refers to asparagine 
residues that are part of a glycosylation sequon and N refers to asparagine 
residues that are not
A: All clades
Position Donor 36 1 2 3 4
295 N N* (50.2) I (12.9) V (12.6) T (8.8)
301 N* N* (79.1) N (10.5) G (2.1) T (1.4)
307 V I (61.4) V (16.8) S (8.8) M (3.7)
308 H R (34.9) H (25.1) I (8.6) T (6.9)
320 G G (75.1) T (8.1) N (6.2) E (2.7)
321 E D (45.0) E (22.7) A (7.2) Q (5.5)
322 V I (89.4) V (6.9) G (1.0) T (0.4)
325 N D (78.3) N (16.9) I (1.2) K (0.8)
326 P I (94.6) T (1.2) G (1.0) P (0.8)
330 F H (68.9) Y (25.7) F (1.8) Q (1.1)
332 T N* (69.9) E (8.5) T (5.9) N (4.8)
334 N* S (69.4) N* (23.2) T (2.8) N (2.2)
B: clade CRF02_AG
Position Donor 36 1 2 3 4
295 N N* (68.6) T (10.7) I (9.1) N (4.1)
301 N* N* (83.4) N (5.8) G (3.3) K (1.6)
307 V V (62.8) I (21.5) S (6.1) G (2.5)
308 H R (64.5) H (20.7) V (5.8) M (1.7)
320 G G (81.8) T (6.6) N (3.3) D (3.3)
321 E D (56.2) E (21.5) A (7.4) G (5.0)
322 V I (90.1) V (7.4) T (0.8) Y (0.8)
325 N D (71.9) N (24.0) G (2.5) K (1.7)
326 P I (96.7) D (1.7) T (0.8) K (0.8)
330 F H (74.4) Y (21.5) S (1.7) Q (0.8)
332 T N* (81.0) T (6.6) N (4.1) K (1.7)
334 N* S (81.8) N* (14.9) T (1.7) V (0.8)
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27], PGT130 is better able to neutralize the N334 vari-
ant donor viruses compared to PGT128, but requires the 
N295 and N301 glycans to do so.
To investigate whether PGT128 and PGT130 were able 
to bind the Env of neutralization resistant viruses we per-
formed ELISA assays with captured gp120 from lysed 
pseudoviruses. The pattern of PGT128 binding the Env 
mutants was consistent with that seen for neutralization 
(Additional file 1: Figure S3, and Figs. 2b and 3a). However, 
PGT130 bound poorly to some gp120s when neutraliza-
tion of the corresponding virus was potent, e.g. 7AA N295 
N334 (Additional file  1: Figure S3, and Figs.  2c and 3b). 
This is consistent with observations that PGT130 binds 
poorly to some monomeric gp120s (unpublished data).
Addition of V1 loop glycans as a potential escape strategy
We have previously observed that removal of V1 loop 
glycan sites can increase neutralization sensitivity of 
certain less mutated nAbs [26] and this has also been 
observed for the PGT121 bnAb family [24, 38]. To inves-
tigate whether V1 loop glycan addition could be a poten-
tial escape strategy in the donor 36 virus, we removed 
the three V1 loop glycans that were present in the iso-
lated virus sequence (N137, N144 and N151), alone and 
in combination, from the 7AA N332 and 7AA N295 
N334 variants and measured the impact on neutraliza-
tion sensitivity of PGT128, PGT130, 95H 71L and 74H 
3L (Fig.  4a–d and Additional file  1: Figure S4). Due to 
the preference for N334 variant viruses, 74H 3L was 
only tested on the 7AA N295 N334 variant [26]. Unlike 
observations for some other viruses [26], removal of V1 
loop glycans individually did not confer neutralization 
sensitivity to 74H 3L (Additional file 1: Figure S4A), nor 
did it greatly increase neutralization sensitivity to 95H 
71L, PGT128 or PGT130 (Additional file 1: Figure S4A). 
When these mutations were added in pairs to 7AA N295 
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Fig. 3 PGT128 and PGT130 show different dependencies on V3 loop N-linked glycosylation sites. Neutralization of donor 36 viruses with an N334 
glycan site by bnAbs a PGT128 and b PGT130. Neutralization of donor 36 viruses with an N332 or N334 glycan site by Abs c 95H 71L (less mutated 
variant of PGT128, 12 % mutated in VH and VL) and d 74H 3L (less mutated variant of PGT130, 13 % mutated in VH and VL). Importance of N301 
glycan in the donor 36 virus for neutralization by bnAbs e PGT128 and f PGT130. The Asn at position N301 was mutated to alanine in the 3AA N332, 
3AA N295 N332, 3AA N295 N334, 7AA N295 N332 and 7AA N295 N334 variant viruses using site-directed mutagenesis and impact on neutralization 
measured. The N301A variants are shown with the dotted line
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N334, an enhancement in neutralization plateau and 
potency for PGT128 and PGT130 was observed (Fig. 4a, 
b), and 95H 71L was now able to neutralize this virus 
(Fig.  4c). Introduction of all three mutations simultane-
ously further increased the neutralization potency of 
95H 71L (Fig.  4c) although 74H 3L remained unable to 
neutralize the virus (Fig.  4d). Removal of V1 loop gly-
cans in the 7AA N332 variant virus had limited impact 
on neutralization potency of PGT128 and 95H 71L (Fig-
ure S4B). To confirm that the V1 glycan site deletion 
mutants were not leading to a general increase in neu-
tralization sensitivity, neutralization by a wider panel of 
HIV bnAbs (PG9, PGT151, PGT145 and PGT135) and 
HIVIG (pooled IgG from HIV infected individuals) were 
tested against 7AA N295 N334 and V1 deleted mutant 
(Additional file  1: Figure S5). No enhancement of neu-
tralization was observed suggesting the effect observed 
is specific for this bnAb family. These data may indicate 
addition of V1 loop glycans as a potential escape mech-
anism from early nAbs for the donor 36 virus, although 
longitudinal virus sequences would be required to con-
firm this. The importance of V1 loop glycans for bnAb 
evolution has also been suggested for the PGT121 family 
where addition of a glycan at position N137 is thought to 
drive maturation of the bnAb response [38].
V3 protein residues facilitate escape in other viruses 
to differing extents
As mentioned above, previous studies have not reported 
V3 mutations that lead to neutralization resistance by 
PGT128 [11, 24, 29, 31]. To determine whether the V3 
mutations required to restore neutralization sensitivity to 
the donor 36 virus could facilitate neutralization resistance 
in the context of other viruses, we next prepared a panel 
0.0001 0.001 0.01 0.1 1 10 100
-20
0
20
40
60
80
100
120
Ab concentration (µg/ml)
%
 n
eu
tra
liz
at
io
n
0.0001 0.001 0.01 0.1 1 10 100
-20
0
20
40
60
80
100
120
Ab concentration (µg/ml)
%
 n
eu
tra
liz
at
io
n
0.0001 0.001 0.01 0.1 1 10 100
-20
0
20
40
60
80
100
120
Ab concentration (µg/ml)
%
 n
eu
tra
liz
at
io
n
0.0001 0.001 0.01 0.1 1 10 100
-20
0
20
40
60
80
100
120
7AA N295 N334
7AA N295 N334 N144A N151A 
7AA N295 N334 N137A N144A N151A
7AA N295 N334 N137A N151A
7AA N295 N334 N137A N144A
Ab concentration (µg/ml)
%
 n
eu
tra
liz
at
io
n
a   PGT128 c   95H 71L
b   PGT130 d  74H 3L
Fig. 4 V1 loop glycan addition as a potential escape strategy. V1 loop glycans were removed using an Asn to Ala substitution. Single (see Additional 
file 1: Figure S4A), double and triple V1 loop glycan mutants were prepared for the 7AA N295 N334 variant. Neutralization was determined for a 
PGT128, b PGT130, c 95H 71L and d 74H 3L
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of mutant viruses harbouring these mutations singly and 
in combination. Mutations were focussed at positions 307, 
321, 325, 326 and 330 in the clade B viruses, BaL, JR-FL 
and 92BR020. The impact on neutralization sensitivity by 
the full PGT128 bnAb family was measured (Fig. 5).
Both I307A and I307V were tested to maximise the 
chances of seeing a neutralization effect. The I307A 
mutation reduced neutralization potency for the major-
ity of the bnAbs and in some cases no neutralization was 
observed at concentrations of up to 20  μg/mL (Fig.  5). 
The I307V mutation had only a very modest effect on 
neutralization potency for JR-FL suggesting that individ-
ual subtle changes at this position can be tolerated. The 
I326P mutation reduced neutralization potency for the 
majority of bnAbs, although the effect was less dramatic 
for 92BR020. However, mutation at the 326 position to 
Thr (2nd most commonly observed in the Los Alamos 
database (Table 1) or to Ala had no effect on neutraliza-
tion sensitivity of JR-FL. Mutations H330Y and H330F 
were both tested at position 330 as these residues are 
most commonly found in viruses containing a glycan at 
position N334 rather than position N332. Both mutations 
had similar but less pronounced effects compared to the 
I307A and I326P mutations and showed a reduction of 
neutralization potency and/or neutralization plateau for 
some bnAbs but never abolished neutralization com-
pletely (data not shown). An H330A mutation in JR-FL 
also had a similar impact on neutralization. Mutation at 
position 321 and 325 alone (D321A and D325N) had no 
effect on neutralization. Antibody 95H 71L was much 
more sensitive to the V3 mutations with larger increases 
in IC50 observed and/or bigger reductions in neutraliza-
tion plateau compared to PGT128 suggesting increased 
somatic hypermutation is required for tolerating diversity 
JRFL IC50 WT  
(µg/mL)
I307V I307A E321A D325N I326P I326A I326T H330F H330Y H330A H330F E321A
H330F 
D325N 
I326T
PGT125 0.016 3.6 191 1.3 3.4 157 0.9 1.5 9.0 188 15.6 0.7 >424
PGT126 0.024 3.5 24.8 1.0 1.2 19.8 1.6 1.0 69.3 10.4 6.6 3.1 143
PGT127 0.030 4.0 80.1 1.5 3.8 >800 2.9 1.8 84.1 12.3 20.9 237 >484
PGT128 0.021 3.3 248 1.2 2.3 >3000 1.8 1.3 3.2 1.3 1.9 32.8 90.2
PGT130 0.081 5.8 >300 0.7 0.2 >300 0.7 0.3 0.5 0.5 1.0 0.4 1.3
PGT131 0.318 >62 >80 1.0 2.7 >80 23.0 23.0 0.4 0.5 >56 0.1 >2.7
95H 71L 0.103 0.2 99.9 1.1 5.1 39.9 1.0 0.7 39.9 44.9 >174 >174 >174
PGV04 0.670 3.6 17.4 1.3 1.3 0.2 1.7 1.2 1.0 1.0 0.9 0.7 1.9
BaL IC50 WT  
(µg/mL)
I307V I307A D325N I326P I326T H330F H330Y I326T H330F
D325N 
I326T 
H330F
PGT125 0.020 0.9 >500 496 >500 0.6 5.2 59.3 6.0 >655
PGT126 0.019 0.7 >500 1.0 >500 0.7 5.9 3.1 19.5 91.2
PGT127 0.018 0.6 >550 4.8 >550 0.6 27.7 3.3 254 >412
PGT128 0.007 0.7 >1500 1.3 >1500 1.1 4.6 1.6 7.1 13.0
PGT130 0.039 0.8 >500 25.1 >500 0.5 1.7 1.8 9.1 24.0
PGT131 0.570 0.5 >35 >4 >35 11.8 0.6 0.4 25.2 >118
95H 71L 0.037 3.1 >500 9.3 >500 0.5 >500 >500 476 135
PGV04 0.006 1.7 3.9 1.3 1.4 0.7 0.9 1.1 1.5 0.7
92BR020 IC50 WT  
(µg/mL)
I307V I307A I326P H330F H330Y
D325N 
I326T 
H330F
 D321E 
D325N 
I326T 
H330F
PGT125 0.016 2.0 6.8 1.0 0.6 32.8 59.9 119 > 100
PGT126 0.014 1.5 3.3 0.9 0.7 0.9 1.7 2.6 36-100
PGT127 0.039 0.9 54.5 57.0 24.8 34.7 >256 >230 10-35
PGT128 0.010 0.9 1.8 1.7 0.3 0.4 1.0 2.5 3-9.9
PGT130 0.160 0.2 >330 >330 0.2 0.2 0.4 0.3 < 3
PGT131 0.295 0.3 >70 >70 0.1 0.1 67.8 22.4
95H 71L 0.106 2.4 683 5.2 219 54.6 366 222
PGV04 0.025 0.9 0.7 1.0 1.5 1.4 1.5 1.1
Fold change
Fold change
Fold change
Fig. 5 Importance of V3 loop residues at positions 307, 321, 325, 326 and 330 for neutralization by the donor 36 bnAb family. Mutations shown 
to confer neutralization sensitivity to the donor 36 virus were introduced alone or in combination into BaL, JR-FL and 92BR020 pseudoviruses 
and the impact on neutralization determined for PGTs125-131, 95H 71L and PGV04. Data is reported as fold change in IC50 compared to WT (Fold 
change = IC50 mutant/IC50 WT) and colour coded according to the figure key. IC50 values for each antibody against the wild-type virus is shown for 
reference (in µg/ml)
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in V3. Control bnAb PGV04 was largely unaffected by 
the mutations made.
To investigate whether combinations of these muta-
tions could facilitate escape, we prepared several double, 
triple and quadruple mutants in all three-virus strains. In 
general, double mutations had limited additional impact 
on neutralization potency compared to single mutations. 
For JR-FL and BaL, only the D325N +  I326T +  H330F 
triple mutant was prepared as both viruses already had 
a D at position 321. For both triple mutants, neutrali-
zation was completely abolished for PGT125, PGT127 
and PGT131 and neutralization potency was reduced 
for PGT126, PGT128 and PGT130. Similarly, for the 
92BR020 quadruple mutant, PGT125, PGT127 and 
PGT131 had greatly decreased neutralization potency 
but this effect was minimal for PGT126, PGT128 and 
PGT130. In all cases 95H 71L was more sensitive to the 
V3 mutations. Overall, these results highlight the impor-
tance of the V3 loop for neutralization efficiency and as 
a potential viral escape mechanism. Although individual 
mutations had limited effect on neutralization, these 
effects were enhanced when mutations were combined 
as previously observed for the PGT121 bnAb family [24, 
31].
Residues in V3 can modulate promiscuous binding to the 
mannose‑patch
The difference in sensitivity of the 3AA N295 N334 and 
7AA N295 N334 viruses to neutralization by PGT128 
(Fig.  3a) suggests that the ability of the antibody to 
bind promiscuously to the mannose-patch is somewhat 
dependent upon protein residues in the V3 loop. To 
test this hypothesis we reverted the additional V3 resi-
dues R308, D321, V322 and D325 back to WT for both 
the N332 and N334 versions of the 7AA N295 virus and 
measured the impact on neutralization (Fig.  6). For the 
7AA N295 N332 variant these mutations had little or no 
effect on neutralization for both PGT128 and PGT130 
(Fig. 6a, b). However, for the 7AA N295 N334 variant, the 
potency of PGT128 neutralization was reduced by the 
D325N and D321E V332I mutations and PGT130 neu-
tralization was reduced by the D325N mutation (Fig. 6c, 
d). As the I323 and D325 residues have been shown to 
contact the CDRH3 of PGT128 via the protein backbone, 
these findings suggest that certain residues present in the 
V3 protein contact region may be required to help posi-
tion the N334 glycan such that PGT128 and PGT130 can 
bind and this is more apparent for PGT128. Alternatively, 
some side chain binding with the 323IGDIR327 motif may 
occur when the N334 glycan site is present that is not 
observed in the N332 virus. Either way, these data high-
light the importance of V3 residues in promiscuous bind-
ing of donor 36 bnAbs to the mannose-patch.
To further investigate the importance of the V3 loop 
for promiscuous glycan binding, we introduced V3 
mutations into N334 and N332A resistant viruses in an 
attempt to restore PGT128 and PGT130 neutralization 
sensitivity (Fig.  6e–h). We have previously shown that 
PGT128 is unable to neutralize the N332A and N334 var-
iants of clade C virus IAVI C22 and PGT130 has severely 
decreased neutralization potency compared to WT [26, 
27]. Inspection of the sequence revealed that this virus 
lacked a glycan at N295 and had Asn at position 320 and 
Gly at position 321 instead of the more common Gly and 
Asp respectively (Table 1). The N320G and G321D muta-
tions were introduced and the N295 glycan site added 
(through a V295N mutation) alone and in combination 
to the N332A and N334 IAVI C22 variants and impact 
on PGTs125–131, 95H 71L and PGV04 neutralization 
determined (Fig.  6e, f, Additional file  1: Figure S6A, B). 
Neutralization by PGT128 could only be restored by 
introduction of the N295 glycan (Fig. 6e and Additional 
file  1: Figure S6A, B), which is consistent with the use 
of this glycan in the absence of N332 [10, 27]. However, 
neutralization of PGT130 could be enhanced through V3 
mutation G321D alone and this was further enhanced 
by addition of the N295 glycan (Fig.  6f and Additional 
file  1: Figure S6A, B). The less mutated bnAb 95H 71L 
remained resistant to all viruses and PGV04 was unaf-
fected (Additional file 1: Figure S6A, B).
We next identified two viruses that naturally have N334 
and N295 glycan sites but are largely resistant to neutrali-
zation by PGTs125-131 and attempted to restore neutral-
ization through mutation of the V3 protein residues alone 
[27]. An E321D mutation was introduced into the clade B 
virus REJO4541.67 but the mutant virus remained resist-
ant to neutralization by PGTs125-131 (data not shown). 
However, when an N325D mutation was introduced into 
clade AC virus 6545.v4.c1, PGT125, PGT128, PGT130 
and PGT131 were able to neutralize the mutant virus 
(Fig.  6g, h and Additional file  1: Figure S6C) and neu-
tralization potency could be further increased through 
addition of the V307I mutation. Combined, these data 
highlight the importance of the V3 loop for modulating 
promiscuous binding of the mannose-patch by this fam-
ily of bnAbs and likely represent an alternative escape 
pathway to glycan site deletion.
Discussion
We have previously shown that PGTs125-131 are pro-
miscuous in their recognition of the mannose-patch and 
are able to neutralize a considerable proportion of viruses 
either lacking the N332 glycan site or with the glycan site 
shifted to the 334 position [27]. This led us to explore 
viral escape mechanisms from this promiscuous glycan-
binding bnAb family using an escape virus isolated from 
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donor 36 as a starting point. We describe three observa-
tions that have implications for HIV-1 vaccine design. 
Firstly, different mutations in the virus isolated from 
donor 36 can restore neutralization sensitivity towards 
bnAbs PGT128 and PGT130, secondly mutations in both 
the protein sequence and glycan positions can lead to 
neutralization resistance, and thirdly, the V3 loop protein 
residues can play an important role in modulating pro-
miscuous binding to the mannose-patch.
We have previously shown that the bnAb response in 
donor 36 is diverse such that two classes of bnAb exist 
[26]. Figure  7 models the different dependencies on V3 
and surrounding glycans for the PGT128 and PGT130 
bnAb classes based on the isolated donor 36 virus. For a 
virus displaying an N332 glycan, PGT128 requires either 
the N295 or N301 glycan for neutralization and addi-
tional mutations in V3 increase the neutralization plateau 
(Fig. 7b). However, for a virus displaying an N334 glycan, 
PGT128 requires both N295 and N301 glycans and is 
more sensitive to mutations in the V3 loop, only neutral-
izing the 7AA variant. PGT130 differs in that neutraliza-
tion of both N332 and N334 containing viruses requires 
both the N295 and N301 glycans (Fig.  7b). PGT130 
dependency on V3 loop mutations for neutralization 
is greatest for N334 viruses although, unlike PGT128, 
it is able to neutralize both the 3AA and 7AA versions. 
Neutralization sensitivity towards the donor 36 virus 
can be conferred for both bnAb classes through addition 
of the N295 glycan site, P326I mutation and shifting of 
the N334 glycan site to N332. However, neutralization 
by PGT128 can also be conferred with the 3AA N332 
mutant and for PGT130, it can be conferred through 
the 3AA N295 mutant. These differences in sensitivity 
towards the host virus might have contributed towards 
divergence of recognition between the two bnAb classes 
(although longitudinal Env sequencing would be required 
to determine this).
We next consider the role of the V3 loop in neutrali-
zation resistance and modulating promiscuous binding 
of the mannose-patch. Neutralization escape via pro-
tein mutation in V3 has not previously been reported 
for PGTs125-131 with the commonly reported escape 
through an N332A or N301A mutation [10, 11, 27]. For 
viruses where an N332A mutation is insufficient for neu-
tralization resistance, a double glycan site deletion (e.g. 
N332A +  N295A) can abolish neutralization [27]. Here 
we extend these observations and demonstrate that 
either combined mutations at positions 321, 325, 326 and 
330 or glycan site deletion/shifting combined with V3 
mutation can also facilitate viral escape. There are limited 
studies determining escape from an N332-bnAb response 
in  vivo. Sadjadpour et  al. reported escape from an 
N332-dependent bnAb response in an SHIVAD8 infected 
macaque mainly occurred through stepwise substitution 
of amino acids in the C-terminal end of the V3 loop [31]. 
A minimum of two mutations (D321A and I323T) was 
a
b
c
d
e
f
g
h
Fig. 6 Importance of V3 loop residues for promiscuous binding of the mannose-patch. V3 loop residues in the a, b 7AA N295 N332 and c, d 7AA 
N295 N334 variants were mutated to WT and the impact on neutralization measured for PGT128 and PGT130. Mutations in the V3 loop were made 
to e, f IAVI C22 N334 and g, h 6545.v4.c1 to confer neutralization sensitivity by PGT128 and PGT130
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required for escape from the serum antibodies (although 
these mutations did not confer resistance to PGT128 or 
PGT130). In contrast, Moore et  al. reported escape in 
two chronically infected individuals occurred through 
shifting of the N332 glycan site to N334 [30]. Accompa-
nying mutations at positions 325 and 330 were observed 
in some escape viruses although the importance of these 
mutations was not determined. Interestingly, despite 
the prevalence of mannose-patch binding bnAbs within 
HIV-1 infected individuals [18], 90  % of viruses have a 
glycan at N332 or N334 [27]. This may indicate an unre-
alized selection pressure for Env to maintain the N332/
N334 glycan site for Env stability or viral fitness. Further 
longitudinal analysis of viral sequences from N332A sen-
sitive HIV donors may reveal a preference for escape via 
V3 rather than glycan-site deletion or shifting.
Neutralization resistance via mutation in V3 is emerg-
ing as a common feature for mannose-patch binding 
bnAb families, e.g. PGT121 and PGT135 bnAb families 
[9, 24]. However, as mentioned above, different muta-
tions facilitate resistance for the different antibody lin-
eages [9, 24, 31] and this is further exemplified here by 
the different mutations required to confer neutraliza-
tion sensitivity against the donor 36 virus by PGT121 
and PGT128/130. These differences in V3 escape for 
N332-dependent bnAb lineages further highlight the 
diverse mechanisms used by bnAbs to bind the N332 
‘supersite of vulnerability’ [9] and further support the 
idea that eliciting a diverse bnAb response against this 
epitope may minimize viral escape and increase the 
breadth of protection [27].
It is not clear how protein residues in the V3 loop 
modulate the ability of bnAbs to bind alternative 
arrangements of glycans in the mannose-patch. A 
recent EM structure of PGT128 Fab in complex with 
BG505 SOSIP.664 trimer indicates that the N295 glycan 
would have to move approximately 60 Å to interact with 
PGT128 in the absence of N332 [39]. However, a recent 
crystal structure of PGT128 Fab in complex with BG505 
SOSIP.664 trimer shows the D1 arms of N295 and N332 
are separated by only 5 Å suggesting a minor shift would 
facilitate binding to N295 in the absence of N332 [40]. 
Residues in V3 may help position the N334 or N295 gly-
can to enable simultaneous binding of the N334/N295 
and N301 glycan sites and V3 loop. Alternatively, when 
the N334 glycan is present interaction with V3 may be 
more dependent on side-chain than backbone interac-
tions and therefore bnAbs can tolerate less variation in 
V3 for an N334 virus. Additional structural studies of 
PGT128 and PGT130 Fab with Env proteins harbouring 
an N334 glycan site would provide greater insight into 
how the V3 mutations impact the epitope recognition by 
this family of bnAbs.
These observations have implications for immuno-
gen design. As the most efficacious vaccine response 
would likely include both the PGT128 and PGT130 
bnAb classes [26, 27], immunogens displaying differ-
ent arrangements of glycans in the V3 region may be 
Fig. 7 Model depicting the differences in dependency on the V3 loop and surrounding glycan sites (N295, N301, N332/N334) for PGT128 and 
PGT130 based on the donor 36 virus. a Model of bnAb epitope on the HIV trimer. b PGT128 neutralizes the N332 viruses very potently and requires 
glycosylation at either position N295 or N301. However, PGT128 can only neutralize the N334 variant when both glycan sites at N295 and N301 are 
present. PGT130 on the other hand neutralizes both N332 and N334 variants very potently, but depends on the presence of both glycan sites at 
N295 and N301. Differences are also observed in the V3 loop residues that should be reverted to confer and improve neutralization. PGT128 is less 
dependent on the V3 loop composition when N332 is glycosylated. It neutralizes the 1AA mutant virus potently and with increasing changes in V3, 
its potency, as well as the neutralization plateau, increases. If the glycan is at position N334, the bnAb only neutralizes the 7AA variant. The neutrali-
zation potency of PGT130, however, decreases slightly with increasing changes in the V3 loop in the N332 virus variants, hinting that PGT130 is less 
dependent on V3 loop conformation. In the presence of the N334 glycan, PGT130 only neutralized the 3AA and 7AA mutants and potency, as well 
as the neutralization plateau, increases when more changes were introduced. The dependencies are highlighted in accordance with the figure key
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required to elicit a diverse bnAb response as observed 
in donor 36. We suggest a priming immunogen should 
include the most conserved V3 residues and the 
N295 and N332 glycan sites but have fewer V1 loop 
glycans to enhance epitope recognition. Sequential 
booster immunogens should have shifted glycan sites 
and include N295/N334, N332 alone or N334 alone, 
although it is not clear from this data which order 
would be most optimal and in  vivo models will be 
required to determine this. Our results also highlight 
the importance of V3 for immunogen design aimed 
at inducing bnAbs that can bind promiscuously to the 
mannose-patch. Current immunogen design strate-
gies commonly incorporate a truncated ‘mini’ V3 [41]. 
However these data suggest a full V3 loop is likely 
required to generate bnAbs that can tolerate the inher-
ent level of variability in V3. Therefore, some variation 
in the V3 region should be incorporated into these 
glycan-shifted immunogens to help generate bnAbs 
that can tolerate mutation in the V3 region. This is sup-
ported by the observation that the less mutated bnAb, 
95H 71L, is more sensitive to protein changes in the V3 
region. As the V3 requirements appear to differ for the 
different bnAb lineages that recognize this region of 
Env, different immunogens may be optimal for eliciting 
certain bnAb lineages.
Conclusions
In summary, we show that neutralization resistance from 
this bnAb family can occur via mutation of protein resi-
dues in the V3 region, as well as shifting and/or dele-
tion of N-linked glycans. We show that residues in V3 
can have an important impact on the ability of donor 36 
bnAbs to bind promiscuously to the mannose-patch. We 
further show that different mutations in the escape virus 
isolated from donor 36 can restore neutralization sensi-
tivity towards the two bnAb branches. These differences 
may have led to divergence in mannose-patch recogni-
tion (although longitudinal analysis would be required to 
prove this). These observations highlight the importance 
of the V3 loop for design of immunogens capable of elic-
iting Abs similar to the diverse family of bnAbs described 
here.
Methods
Ethics statement
Plasma was obtained from donor 36, an HIV-1 infected 
donor from the IAVI Protocol G cohort [42]. All human 
samples in Protocol G were collected with written 
informed consent under clinical protocols approved by 
the Republic of Rwanda National Ethics Committee, the 
Emory University Institutional Review Board, the Univer-
sity of Zambia Research Ethics Committee, the Charing 
Cross Research Ethics Committee, the UVRI Science and 
Ethics Committee, the University of New South Wales 
Research Ethics Committee. St. Vincent’s Hospital and 
Eastern Sydney Area Health Service, Kenyatta National 
Hospital Ethics and Research Committee, University 
of Cape Town Research Ethics Committee, the Interna-
tional Institutional Review Board, the Mahidol Univer-
sity Ethics Committee, the Walter Reed Army Institute of 
Research (WRAIR) Institutional Review Board, and the 
Ivory Coast Comité National d’Ethique des Sciences de la 
Vie et de la Santé (CNESVS).
Amplification and expression of donor HIV‑1 gp160 
sequences
HIV Env sequence was determined as previously 
described [43]. Briefly, virus was pelleted by centrifu-
gation of patient plasma (20,400  g, 1  h). Viral particles 
were lysed by resuspension in lysis buffer (4 M guanidine 
thiocyanate, 0.1  M Tris HCl, pH 8.0, 0.5  % sodium lau-
ryl sarcosine, and 1 % dithiothreitol). RNA was extracted 
using oligo(dT) linked to magnetic beads (Dynal, Oslo, 
Norway) and cDNA was synthesised in a standard RT 
reaction using oligo(dT) primers and Thermoscript RT 
enzyme (Invitrogen, Gaithersburg, MD). Env regions 
were amplified with BD Advantage 2 PCR Enzyme Sys-
tem (Clontech, Mountain View, CA) using a forward and 
reverse primer containing the PinAI and MluI restric-
tion sites respectively. PCR products were digested with 
PinAI and MluI, purified by agarose gel electrophoresis 
and ligated to PinA1 and MluI-digested envelope expres-
sion test vector (eETV). Ligation reactions were used to 
transform competent E. coli and the expression plasmids 
were purified using silica column chromatography (Qia-
gen, Valencia, CA). Colonies were picked and screened 
by a rapid single replication cycle assay. One viable viral 
clone was identified and selected for sequencing and fur-
ther testing.
The Env sequence was synthesised by GENEWIZ 
(South Plainfield, NJ) and cloned into the pSVIII vector 
using the KpnI and XhoI restriction sites for use in pseu-
dovirus assays.
Envelope and antibody mutations
Mutations in the HIV-1 envelope glycoproteins or 
antibody expression plasmids were introduced using 
QuikChange site-directed mutagenesis (Stratagene, La 
Jolla, CA). Mutations were verified by DNA sequenc-
ing (Eton Biosciences, La Jolla, CA and MWG Eurofins, 
Germany).
Pseudovirus production and neutralization assays
To produce pseudoviruses, plasmids encoding Env were 
co-transfected with an Env-deficient genomic backbone 
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plasmid (pSG3∆Env) in a 1:2 ratio with the transfection 
reagent PEI (1  mg/mL, 1:3 PEI:total DNA, Polysciences) 
into HEK 293T cells [44, 45]. Pseudoviruses were harvested 
72 h post transfection for use in neutralization assays.
Neutralizing activity was assessed using a single round 
replication pseudovirus assay with TZM-bl target cells, 
as described previously [44, 45]. Briefly, the antibody or 
HIVIG (HIV hyperimmune globulin) was serial diluted in 
a 96 well flat bottom plate and pre-incubated with virus 
for 1 h at 37 °C. Cells at a concentration of 20,000 cells/
well (supplemented with 10 μg/ml DEAE-Dextran for all 
donor virus variants) were added to the virus/antibody 
mixture and luminescence was quantified 72 h following 
infection via lysis and addition of Bright-Glo™ Luciferase 
substrate (Promega). Dose–response curves were fitted 
using nonlinear regression (GraphPad Prism) to deter-
mine IC50 values.
Gp120 ELISA
For binding to gp120 isolated from pseudovirus, virus 
was collected 3  days post transfection, supernatants 
were spun down at 300 g for 5 min, and virus was lysed 
with 1  % NP-40 at room temperature (RT) for 30  min. 
Enzyme-linked immunosorbent assay (ELISA) plates 
were coated overnight at 4 °C with anti-gp120 Ab D7324 
(Aalto Bio Reagents, Dublin) at a concentration of 3 μg/
ml in PBS. Plates were washed 4 times with PBS-T (PBS 
with 0.05 % Tween-20) and blocked for 1 h with 100 μl 
5  % non-fat milk in PBS-T. Lysed virus was added at 
50 μl/well and incubated for 2 h and washed 4 times with 
PBS-T. Serial dilutions of bnAb in 5 % nonfat milk/PBS-T 
were incubated for 2 h. Unbound antibody was removed 
by washing four times as described above. 50  μl of bio-
tin conjugated rabbit anti-human Fc antibody was added 
(1:1000), incubated for 30 min and washed 4 times. Bind-
ing was detected with streptavidin–alkaline phosphatase 
conjugate (1:1000; BioRad), and p-nitrophenol phosphate 
substrate (Sigma) at 405 nm.
Antibody expression and purification
Antibody plasmids were co-transfected at a 1:1 ratio in 
293 freestyle cells using 293fectin (Invitrogen) or with the 
transfection reagent PEI (1  mg/mL, 1:3 PEI:total DNA, 
Polysciences). Transfections were performed accord-
ing to the manufacturer’s protocol and antibody super-
natants were harvested 4  days following transfection. 
Antibody supernatants were purified over a protein A 
column, eluted with 0.1  M Glycine (pH 3.5), and buffer 
exchanged into PBS.
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Additional file
Additional file 1: Figure S1. Neutralization of donor 36 WT and mutated 
viruses by the remaining donor 36 bnAbs. A PGT125, B PGT126, C PGT127, 
and D PGT131. Figure S2. Importance of I307, I326, Y330 and N332 
for neutralization of 7AA N332 variant virus. Residues at positions 307, 
326, 330 and 332 were reverted to WT and the impact on neutralization 
measured for A PGT128, B PGT130 and C PGV04. Figure S3. Binding to 
Env variants in ELISA. Gp120 from lysed pseudovirions was captured using 
an anti-gp120 antibody (Ab D7324, Aalto Bio Reagents, Dublin) and bind-
ing by a A PGT128, B PGT130 and C PGV04 measured. Binding to gp120 
closely matched neutralization for PGT128 however binding by PGT130 
was reduced. Figure S4. Dependency on V1 loop glycans for neutraliza-
tion by donor 36 bnAbs. A Neutralization of 7AA N295 N334 virus variants 
lacking individual V1 loop glycans. B Neutralization of 7AA N332 virus 
variants lacking individual V1 loop glycans. Figure S5. Dependency on 
V1 loop glycans for neutralization by a panel of HIV bnAbs and HIVIG. 
Neutralization of 7AA N295 N334 virus variants lacking all three V1 loop 
glycans. A PGT135, B PG9, C PGT145, D PGT151, E HIVIG (HIV hyperim-
mune globulin) and F PGV04. Figure S6. Residues in V3 are important 
for promiscuous binding of the mannose-patch. V3 residues in A IAVI 
C22 N332A, B IAVI C22 N334 and C 6545.v4.c1 were mutated to confer 
neutralization by the PGTs125-131. Numbers represent IC50 values for each 
antibody and are reported as µg/ml.
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